Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease.
Marquis-Gravel G, Stebbins A, Wruck LM, Roe MT, Effron MB, Hammill BG, Whittle J, VanWormer JJ, Robertson HR, Alikhaani JD, Kripalani S, Farrehi PM, Girotra S, Benziger CP, Polonsky TS, Merritt JG, Gupta K, McCormick TE 3rd, Knowlton KU, Jain SK, Kochar A, Rothman RL, Harrington RA, Hernandez AF, Jones WS.
Marquis-Gravel G, et al. Among authors: kochar a.
J Am Heart Assoc. 2024 Feb 20;13(4):e026921. doi: 10.1161/JAHA.122.026921. Epub 2024 Feb 13.
J Am Heart Assoc. 2024.
PMID: 38348779
Free PMC article.
Clinical Trial.
METHODS AND RESULTS: In the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) trial, patients with atherosclerotic cardiovascular disease were randomized to daily aspirin doses of 81 mg or 325 mg. ...
METHODS AND RESULTS: In the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) trial, …